SRDX News and Press, Surmodics Inc. From 02/09/21

Surmodics (SRDX): Q4 Non-GAAP EPS of $0.02 beats by $0.11; GAAP EPS of -$0.02 beats by $0.12.Revenue of $22.3M (-1.3% Y/Y) misses by $0.07M.Shares +2.2% PM.Press Release For further details see: Surmodics EPS beats by $0.11, misses on revenue

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 first quarter ended December 31, 2020. Summary of First Quarter and Recent Highlights Revenue o...

Webcast is Live at 7:30 a.m. (CT) Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal 2021 conference call on Tu...

SurVeil™ Drug Coated Balloon (DCB) demonstrates non-inferior safety and efficacy, while using a substantially lower drug dose, vs. the IN.PACT ® Admiral ® DCB for treatment of femoropopliteal lesions. Surmodics, Inc. (NASDAQ:SRDX), a leading provider...

Dr. Kenneth Rosenfield to share study results Jan. 25 in late-breaking trial session Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 12-month data from its TRANSCEND cl...

Study finds 100 percent target lesion patency at 30 days; 90.9 percent of patients free from revascularization at 6 months Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 6...

The following slide deck was published by Surmodics, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Surmodics, Inc. 2020 Q4 - Results - Earnings Call Presentation

Surmodics, Inc. (SRDX) Q4 2020 Earnings Conference Call November 4, 2020 5:00 PM ET Company Participants Timothy Arens - Chief Financial Officer Gary Maharaj - President and Chief Executive Officer Thomas Greaney - Chief Operating Officer of Medical Devices Conference Call Participants Brooks...

Surmodics (SRDX): Q4 Non-GAAP EPS of -$0.18 misses by $0.10; GAAP EPS of -$0.22 misses by $0.06.Revenue of $22.5M (-27.0% Y/Y) beats by $1.73M.FY21 guidance: Due to the continued uncertainty surrounding the duration and magnitude of the COVID-19 pandemic, the Company is not providing financia...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 fourth quarter ended September 30, 2020. Summary of Fourth Quarter and Recent Highlights Revenu...